Business
GMT: Net loss widened to PLN -11.2m as R&D continued, with equity raises ensuring 12+ months liquidity
GMT: Net loss widened to PLN -11.2m as R&D continued, with equity raises ensuring 12+ months liquidity
About this update from Genomtec Sa
2024 saw continued R&D focus, deepening net loss (PLN -11.2m), and major equity raises to fund operations. Commercialization of Genomtec ID and OncoSNAAT is targeted via M&A or licensing, with sufficient liquidity for at least 12 months.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.